Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe - PubMed (original) (raw)
Review
Proposed treatment guidelines for HER2-positive metastatic breast cancer in Europe
M J Piccart. Ann Oncol. 2001.
Free article
Abstract
The human epidermal growth factor receptor-2 (HER2) is overexpressed/amplified in 20%-30% of human breast tumors and is a marker for a poor prognosis. For these reasons, HER2 has been selected as a therapeutic target for breast cancer treatment. Oncologists can no longer ignore the importance of HER2 status for treatment algorithms in breast cancer. In light of the consequences of HER2 status on treatment selection, further research is warranted to refine and standardize HER2 testing in order to minimize false-negative results and optimize selection of treatment pathways. The anti-HER2 monoclonal antibody (MAb) trastuzumab (Herceptin) has proven valuable in treating HER2-positive, advanced-disease patients. and the availability of this novel biologic agent has important implications for clinical practice. This review describes a set of guidelines based on the current options for treatment of breast cancer. Two important factors have been taken into account in compiling these recommendations: (1) the lack of level I evidence to convincingly demonstrate the value of HER2 as a predictive marker for resistance or sensitivity to chemo- and hormonal therapy, and (2) the recently published pivotal phase II and III trial data proving the efficacy of trastuzumab as a single agent and in combination with chemotherapy in HER2-positive metastatic breast cancer.
Similar articles
- HER2--a discussion of testing approaches in the USA.
Thor A. Thor A. Ann Oncol. 2001;12 Suppl 1:S101-7. doi: 10.1093/annonc/12.suppl_1.s101. Ann Oncol. 2001. PMID: 11521714 - The predictive value of HER2 in breast cancer.
Piccart M, Lohrisch C, Di Leo A, Larsimont D. Piccart M, et al. Oncology. 2001;61 Suppl 2:73-82. doi: 10.1159/000055405. Oncology. 2001. PMID: 11694791 Review. - Closing remarks and treatment guidelines.
Piccart M. Piccart M. Eur J Cancer. 2001 Jan;37 Suppl 1:S30-3. Eur J Cancer. 2001. PMID: 11167089 Review.
Cited by
- A Single-Nucleotide Polymorphism in 3'-Untranslated Region of Endothelin-1 Reduces Risk of Dementia After Ischemic Stroke.
Ma W, Fu Q, Zhang Y, Zhang Z. Ma W, et al. Med Sci Monit. 2016 Apr 23;22:1368-74. doi: 10.12659/msm.895888. Med Sci Monit. 2016. PMID: 27106952 Free PMC article. - The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives.
Papadmitriou K, Trinh XB, Altintas S, Van Dam PA, Huizing MT, Tjalma WA. Papadmitriou K, et al. Facts Views Vis Obgyn. 2015;7(3):176-80. Facts Views Vis Obgyn. 2015. PMID: 26977267 Free PMC article. - Association between miR-125a rs12976445 and survival in breast cancer patients.
Jiao L, Zhang J, Dong Y, Duan B, Yu H, Sheng H, Huang J, Gao H. Jiao L, et al. Am J Transl Res. 2014 Nov 22;6(6):869-75. eCollection 2014. Am J Transl Res. 2014. PMID: 25628797 Free PMC article. - Aggressive treatment for hepatic metastases from breast cancer: results from a single center.
Polistina F, Costantin G, Febbraro A, Robusto E, Ambrosino G. Polistina F, et al. World J Surg. 2013 Jun;37(6):1322-32. doi: 10.1007/s00268-013-1986-9. World J Surg. 2013. PMID: 23474856 - The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?
Newsome BW, Ernstoff MS. Newsome BW, et al. Br J Clin Pharmacol. 2008 Jul;66(1):6-19. doi: 10.1111/j.1365-2125.2008.03187.x. Epub 2008 May 22. Br J Clin Pharmacol. 2008. PMID: 18503606 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous